What SolarBiotech does
SolarBiotech describes itself as a bioprocess development company that takes synthetic biology products from the laboratory to commercial production. The website tagline, making sustainable synthetic biology viable since 2019, dates the business to that year. Legal names on the pages include Solar Bioprocessing, LLC, and the group trades under the name Pictor Biotech Inc.
The offer is a service rather than a branded ingredient. Customers bring a strain or a process, and the company supplies upstream fermentation, downstream processing and manufacturing campaigns. The site stresses cost, yield and reproducibility as the targets of process development, the parameters that decide whether a recombinant food protein reaches an acceptable price.
Product types named on the homepage include enzymes, proteins, natural products, fats and oils, and biopolymers. Market segments range from food and beverage to cosmetics, human health, agricultural chemicals and industrial materials. Food-grade enzymes and functional proteins, yeast biomass for nutrition and proteins for human health appear in the list, so protein work is one area among several.
Host organisms and process scope
The capabilities page names five host systems: the methylotrophic yeast Pichia pastoris, baker’s yeast Saccharomyces cerevisiae, filamentous fungi including the Dyadic C1 expression system, Escherichia coli and microalgae. Each host has different strengths. Yeasts secrete folded proteins into the broth, bacteria give fast growth but often retain product inside the cell, and fungi suit enzyme secretion at high titre.
Three service areas are described. Scale-up and process development turns laboratory success into industrial processes. Fermentation and bioprocessing covers small molecules and recombinant proteins across the platforms listed above. Manufacturing offers multi-scale fermentation and flexible campaign design to match commercial demand, which suits customers who need a few batches a year rather than a dedicated plant.
For readers of an ingredients database, the relevant connection is yeast protein and related fermentation-derived materials. The company lists yeast biomass for nutrition among its outputs. Any buyer interested in such material would need to define the specification themselves, including protein percentage and microbial limits, and treat SolarBiotech as a manufacturing partner.
Facility and equipment
The homepage places the operation in Norton, Virginia, on 18 acres with two buildings. Fermentation vessels of 6 L, 125 L, 500 L, 4,000 L and 10,000 L allow a stepwise route from bench screening to pilot and commercial batches. Moving through those volumes lets engineers test oxygen transfer, mixing and feeding before the largest vessel.
Downstream equipment is listed by type. High-pressure and bead mill homogenisers break cells open when the product is intracellular. Disc stack centrifuges separate biomass from liquid, microfiltration and ultrafiltration units clarify and concentrate, and freeze and drum dryers convert wet material into stable powders. Throughput and hygiene classification of each line are worth confirming.
The management team is said to bring experience from Novozymes, Thermo Fisher, Albumedix, Inscripta and Conagen, and the homepage claims more than 200 man-years of experience, more than 30 customers and more than 20 synthetic biology products and processes. These are company statements without named references, so a prospective client should ask for case descriptions under a confidentiality agreement.
Corporate structure
A company release dated 23 January 2025 announced that Pictor Biotech, trading as SolarBiotech, GPC Bio and Eleszto Genetika would be unified under single ownership. The three businesses sit in Norton, Virginia, La Rochelle, France, and Budapest, Hungary. The group describes itself as a vertically integrated synthetic biology and biomanufacturing company focused on precision fermentation.
According to the release, the combined group has more than 100 engineers, scientists and biotech executives. Services named include microbial strain and bioprocess development, plant engineering, automation, construction, deployment and large-scale operations. GPC Bio is described as having nearly 20 years of experience designing, automating and deploying biomanufacturing equipment for industrial plants.
The stated rationale was to address restrictions on strain engineering intellectual property and the difficulty of scaling bioprocesses. For customers this suggests the Virginia plant may be offered together with engineering from the European sister companies. The release gave no capacity figures and said integration would continue, so the combined offer should be confirmed directly.
What a buyer would check
Define the product before approaching any contract manufacturer. A recombinant protein for food needs a host with a safe history, a defined expression construct and a purification route that removes host cell protein, nucleic acid and process residues to a specification. Ask the company which of its host organisms have been used for food-grade material and under which regulatory framework.
Confirm the plant’s food credentials. The pages reviewed list no certifications, so request documentation on current good manufacturing practice, food safety audits, allergen controls and cleaning validation between campaigns. A multi-product site that handles enzymes, cannabinoids and industrial materials needs a clear policy on cross-contamination and on which lines may carry food ingredients.
Finally, check economics and ownership of intellectual property. Fermentation titre, yield on sugar, cycle time and downstream recovery set the cost per kilogram, and a tolling agreement should state who owns strains, process data and improvements. Ask for a scale-up plan with decision gates at each vessel size, and for a campaign schedule that matches the buyer’s forecast.